Save
...
Surgery
Oncology
Gastric Cancer
Save
Share
Learn
Content
Leaderboard
Share
Learn
Created by
Megan D
Visit profile
Cards (12)
Risk factors for gastric cancer
Old age
- 70yrs
Male
- x2 more likely
H. Pylori
- 60% of cases
Gastritis
Smoking
Alcohol
Obesity
Diet -
pickled/cured/processed foods
Family History -
10%
of cases
Pernicious anaemia
What is HDGC?
Autosomal dominant
gene mutation that increases risk of the more severe
diffuse gastric cancer
CDH-1
gene mutation which encodes
E-cadherin
, cells become less cohesive promoting cancer development
50%
chance of passing it on increasing gastric cancer risk to
70-80%
at aged 80
Also increases risk for
lobular breast
cancer to 40%
Gastric cancer is the
6th
most common cancer worldwide
The most common location of
gastric cancer
is the
pyloric antrum
followed by the lesser curvature, cardia, fundus and body of the stomach
Signs and symptoms of
gastric cancer
can include
Weight loss
Fatigue
Bleeding -
haematemesis
or
melena
or
anaemia
Nausea and vomiting
Dyspepsia
Bloating
Dysphagia if cancer affects
cardia
of stomach
Troisier's
sign aka
Virchow's
node
A palpable
left supraclavicular
lymph node
Indicates abdominal malignancy
Gold standard diagnostic test for gastric cancer is
endoscopy
with
biopsy
CT
scans are used to asses
TNM stage
0-4, which involves
Tumour size and local tissue involvement
Lymph Node involvement
Metastasis
5 year survival for gastric cancer is
30%
, improves to
90%
if caught in the earliest stage
Gastric cancer is managed with
Endoscopic mucosal resection
in early stage
Partial/total gastrectomy
in late stage
Chemotherapy
Immunotherapy
Adjuvant
chemotherapy is given after surgery to prevent recurrence
Neoadjuvant
chemotherapy is given before surgery to shrink or stop the spread of cancer
Immunotherapy options for gastric cancer:
Trastuzumab - a HER2 inhibitor,
25%
of gastric cancer cases are
HER2
positive
Nivolumab - a
monocloncal antibody
that inhibits
PD1
receptor, increasing antitumor response